Taysha Gene Therapies Inc (NASDAQ: TSHA) has seen a rise in its stock price by 2.85 in relation to its previous close of 2.46. However, the company has experienced a -1.75% decline in its stock price over the last five trading sessions. Seeking Alpha reported 2024-03-19 that Taysha Gene Therapies, Inc. (TSHA) Q4 2023 Earnings Call Transcript
Is It Worth Investing in Taysha Gene Therapies Inc (NASDAQ: TSHA) Right Now?
The stock has a 36-month beta value of 0.35. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for TSHA is 128.62M, and at present, short sellers hold a 13.21% of that float. On April 24, 2024, the average trading volume of TSHA was 2.77M shares.
TSHA’s Market Performance
TSHA’s stock has seen a -1.75% decrease for the week, with a -22.15% drop in the past month and a 68.67% gain in the past quarter. The volatility ratio for the week is 9.00%, and the volatility levels for the past 30 days are at 9.53% for Taysha Gene Therapies Inc The simple moving average for the past 20 days is -8.92% for TSHA’s stock, with a 22.87% simple moving average for the past 200 days.
Analysts’ Opinion of TSHA
Many brokerage firms have already submitted their reports for TSHA stocks, with Piper Sandler repeating the rating for TSHA by listing it as a “Overweight.” The predicted price for TSHA in the upcoming period, according to Piper Sandler is $9 based on the research report published on April 09, 2024 of the current year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see TSHA reach a price target of $1.50, previously predicting the price at $14. The rating they have provided for TSHA stocks is “Hold” according to the report published on February 01st, 2023.
Morgan Stanley gave a rating of “Equal-Weight” to TSHA, setting the target price at $3 in the report published on January 27th of the previous year.
TSHA Trading at -0.68% from the 50-Day Moving Average
After a stumble in the market that brought TSHA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -34.96% of loss for the given period.
Volatility was left at 9.53%, however, over the last 30 days, the volatility rate increased by 9.00%, as shares sank -17.32% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +50.60% upper at present.
During the last 5 trading sessions, TSHA fell by -1.75%, which changed the moving average for the period of 200-days by +295.31% in comparison to the 20-day moving average, which settled at $2.75. In addition, Taysha Gene Therapies Inc saw 42.94% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TSHA starting from Manning Paul B, who purchase 100,000 shares at the price of $1.63 back on Nov 17 ’23. After this action, Manning Paul B now owns 16,566,667 shares of Taysha Gene Therapies Inc, valued at $163,000 using the latest closing price.
Alam Kamran, the Chief Financial Officer of Taysha Gene Therapies Inc, sale 33,000 shares at $2.33 during a trade that took place back on Aug 24 ’23, which means that Alam Kamran is holding 258,042 shares at $76,890 based on the most recent closing price.
Stock Fundamentals for TSHA
Current profitability levels for the company are sitting at:
- -4.66 for the present operating margin
- 0.87 for the gross margin
The net margin for Taysha Gene Therapies Inc stands at -7.38. The total capital return value is set at -0.31. Equity return is now at value -294.04, with -56.40 for asset returns.
Based on Taysha Gene Therapies Inc (TSHA), the company’s capital structure generated 0.36 points at debt to capital in total, while cash flow to debt ratio is standing at -1.73. The debt to equity ratio resting at 0.56. The interest coverage ratio of the stock is -35.01.
Currently, EBITDA for the company is -70.0 million with net debt to EBITDA at 1.18. When we switch over and look at the enterprise to sales, we see a ratio of 25.23. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.06.
Conclusion
To sum up, Taysha Gene Therapies Inc (TSHA) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
